A phase Ib/II study of fruquintinib in combination with SOX and toripalimab as first-line treatment for advanced metastatic gastric/gastroesophageal junction adenocarcinoma (GC/GEJC).

被引：0
|
作者：
Meng, Xiangrui [1 ]
Shan, Zhengzheng [1 ]
Guan, Lulu [1 ]
Dao, Xin [1 ]
Fan, Qingxia [1 ]
Wang, Feng [1 ]
机构：
[1] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期
关键词：
261-492-5651-9270-10662; 298-145-222-184-1022-9124; 261-566-9718-9794; 130-540-543-4790; 261-492-2769; 3282-3306-2666-6279; 3282-3306-4614-3827; 3; 2; 2461; 3216; 1704; 239; 6; 1; 38092-34311; 38092-21759; 38116-38094-8; 38092-20072;
D O I：
10.1200/JCO.2024.42.3_suppl.335
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：335 / 335
页数：1
相关论文
共 50 条
  • [41] A multicentre, open-label phase II study of Irinotecan, capecitabine (Xeloda®), and Oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
    Arthur Lui
    Karen Mulder
    Christine Brezden-Masley
    Michael Vickers
    Jose Monzon
    Hagen Kennecke
    Rakesh Goel
    Larissa Vos
    Sunita Ghosh
    Horia Marginean
    Anthony Fields
    Jean Maroun
    Jennifer Spratlin
    Investigational New Drugs, 2018, 36 : 674 - 682
  • [42] A multicentre, open-label phase II study of Irinotecan, capecitabine (Xeloda®), and Oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
    Lui, Arthur
    Mulder, Karen
    Brezden-Masley, Christine
    Vickers, Michael
    Monzon, Jose
    Kennecke, Hagen
    Goel, Rakesh
    Vos, Larissa
    Ghosh, Sunita
    Marginean, Horia
    Fields, Anthony
    Maroun, Jean
    Spratlin, Jennifer
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (04) : 674 - 682
  • [43] Pembrolizumab for first-line treatment of advanced unresectable or metastatic esophageal or gastroesophageal junction cancer
    Hirose, Toshiharu
    Yamamoto, Shun
    Kato, Ken
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2023, 16
  • [44] Epirubicin, oxaliplatin, and docetaxel (EOD) combination in metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: A phase II study
    Di Lauro, L.
    Giacinti, L.
    Arena, M. G.
    Fattoruso, S. I.
    Foggi, P.
    Lopez, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [45] Camrelizumab combined with SOX in the first-line treatment of unresectable advanced or metastatic gastric/gastroesophageal junction (G/GEJ) adenocarcinoma: A single-arm, prospective, and open-label clinical study.
    Liu, Wenlou
    Qin, Xiaobing
    Zhao, Yang
    Ge, Yan
    Tang, Juanjuan
    Wang, Hongmei
    Han, Zhengxiang
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16090 - E16090
  • [46] A phase II study of toripalimab combined with paclitaxel/carboplatin for the first-line treatment of advanced thymic carcinoma
    Hu, X.
    Zhu, H.
    Feng, Y.
    Lu, J.
    Liu, Y.
    Xing, P.
    Wang, H.
    ANNALS OF ONCOLOGY, 2021, 32 : S1426 - S1426
  • [47] Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma
    Xu, Jianming
    Bai, Yuxian
    Xu, Nong
    Li, Enxiao
    Wang, Buhai
    Wang, Jin
    Li, Xiang
    Wang, Xin
    Yuan, Xianglin
    CLINICAL CANCER RESEARCH, 2020, 26 (17) : 4542 - 4550
  • [48] Multicenter phase I dose escalation and expansion study of pyrotinib in combination with camrelizumab and chemotherapy as first-line treatment for HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma
    Li, Sheng
    Bao, Jun
    Li, Xiaoyou
    Yang, Quanliang
    Xu, Junying
    Chen, Surong
    Feng, Ge
    Gao, Chao
    Feng, Lin
    Lu, Bin
    Miao, Min
    Ni, Xinchu
    Wang, Guofang
    Yang, Lei
    Zhu, Liangjun
    ECLINICALMEDICINE, 2023, 66
  • [49] Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study)
    Pinto, C.
    Di Fabio, F.
    Siena, S.
    Cascinu, S.
    Llimpe, F. L. Rojas
    Ceccarelli, C.
    Mutri, V.
    Giannetta, L.
    Giaquinta, S.
    Funaioli, C.
    Berardi, R.
    Longobardi, C.
    Piana, E.
    Martoni, A. A.
    ANNALS OF ONCOLOGY, 2007, 18 (03) : 510 - 517
  • [50] Phase Ib trial of cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with advanced hepatocellular carcinoma (HCC), gastric or gastroesophageal junction cancer (GC/GEJC), or colorectal cancer (CRC).
    Spencer, Kristen Renee
    Ramsingh, Giridharan
    Mohamed, Nehal
    Pal, Sumanta K.
    Rimassa, Lorenza
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
12345